Drug Profile
ICP 330
Alternative Names: ICP-330Latest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator InnoCare Pharma
- Class Anti-inflammatories; Antipsoriatics; Small molecules
- Mechanism of Action TYK2 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammatory bowel diseases; Psoriasis; Systemic lupus erythematosus
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in China (PO)
- 28 Nov 2023 No recent reports of development identified for preclinical development in Psoriasis in China (PO)
- 28 Nov 2023 No recent reports of development identified for preclinical development in Systemic-lupus-erythematosus in China (PO)